Alnylam Pharmaceuticals, Inc.

Cambridge, Massachusetts, United States alnylam.com

Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development of RNAi therapeutics. The company focuses on genetic-driven and rare diseases with a comprehensive pipeline leveraging their RNA interference platform.

Therapeutic areas

Genetic DiseasesCardiometabolic DiseasesRare Diseases

FDA compliance signals

3 FDA enforcement records linked to this company.

  • 4832025-02-25

    Record maintenance 1 year (except exempt OTC)

  • 4832025-02-25

    Component written specification

  • 4832025-02-25

    Quality control unit review of records

Verified Supplier Partner

Is this Alnylam Pharmaceuticals, Inc.? Get in front of buyers actively sourcing.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Related companies

Aegerion Pharmaceuticals, Inc.
United States
Amicus Therapeutics, Inc.
United States
Andelyn Biosciences, Inc.
United States
ANV Therapeutics Inc.
United States
Armr Sciences Inc.
United States
BioMed Pharmaceuticals Inc.
United States
bluebird bio, Inc.
United States
Blueprint Medicines Corporation
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.

Start free trialBook a demo